Repetitive transcranial magnetic stimulation focusing on patients with neuropathic pain in the upper limb: a randomized sham-controlled parallel trial

Nobuhiko Mori, Koichi Hosomi, Asaya Nishi, Akimitsu Miyake, Tomomi Yamada, Akiyoshi Matsugi, Yasutomo Jono, Chanseok Lim, Hui Ming Khoo, Naoki Tani, Satoru Oshino, Youichi Saitoh, Haruhiko KishimaScientific 2024 · DOI

Abstract

This randomized, blinded, sham-controlled trial evaluated the efficacy of navigation-guided repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) in 30 patients with chronic upper limb neuropathic pain. The protocol involved five daily sessions followed by weekly maintenance for seven weeks. While the primary outcome—reduction in daily pain intensity at week 9—did not reach statistical significance compared to sham, the active rTMS group showed significant improvements in pain-related disability. The treatment was well-tolerated with no serious adverse events, suggesting rTMS may enhance functional outcomes in this patient population.

Introduction

Neuropathic pain, affecting approximately 10% of the population, remains a significant clinical challenge due to its resistance to conventional pharmacological and surgical treatments. Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has emerged as a promising non-invasive neuromodulation technique. Previous research suggested that neuropathic pain in the upper limbs might be particularly responsive to cortical stimulation. This study aimed to rigorously test a high-dose, long-term rTMS protocol specifically tailored for patients with upper limb neuropathic pain.

Methods

The study was a randomized, patient- and assessor-blinded, sham-controlled parallel trial conducted at Osaka University Hospital. Thirty patients with chronic neuropathic pain (baseline score $\ge$ 4/10) were randomized into active rTMS (n=14) or sham-stimulation (n=16) groups.

Intervention Protocol

The active group received 10-Hz rTMS (2000 pulses/session) targeting the M1 hand area, guided by a navigation system. The protocol was divided into an intensive induction phase and a maintenance phase.

Study timeline illustrating the induction phase (D1-D5) and the maintenance phase (W2-W8) leading to the primary endpoint at Week 9.

To maintain blinding, the sham group received stimulation from an identical-looking coil and simultaneous low-current electrical scalp stimulation to mimic the physical sensation of active rTMS—a rigorous control often missing in earlier studies.

Results

The primary outcome was the change in the weekly average of a daily pain diary (Numerical Rating Scale) at week 9.

Pain Intensity and Patient Impression

While both groups showed a downward trend in pain scores, the difference between the active group (0.84 ± 0.31 reduction) and the sham group (0.58 ± 0.29 reduction) was not statistically significant ($p = 0.54$). However, early in the treatment (Day 5), the active group reported significantly higher rates of "minimal improvement" on the Patient Global Impression of Change (PGIC) scale (36% vs. 19%, $p = 0.04$).

Weekly pain diary scores showing the trend of pain intensity for both active and sham groups over the 9-week period.

Functional Improvement

Despite the lack of significant sensory pain relief, the active group demonstrated a statistically significant improvement in the Pain Disability Assessment Scale (PDAS). The active group showed a mean improvement of 8.0 points compared to -0.3 in the sham group ($p = 0.03$). This suggests a "function over feeling" effect, where neuromodulation helps patients manage daily activities better despite persistent pain intensity.

Discussion

The study's failure to meet its primary endpoint may be attributed to several factors, including a small sample size and a potentially over-effective sham control. The use of electrical scalp stimulation in the sham group may have activated "gate control" mechanisms, narrowing the gap between groups. Nevertheless, the significant improvement in pain-related disability is a clinically meaningful finding. Future research should utilize larger cohorts and longer intervention periods to further explore the functional benefits of rTMS in chronic pain management.

Summary updated

Abstract

This study aimed to evaluate the efficacy and safety of navigation-guided repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex in patients with neuropathic pain in the upper limb. This randomized, blinded, sham-controlled, parallel trial included a rTMS protocol (10-Hz, 2000 pulses/session) consisting of five daily sessions, followed by one session per week for the next seven weeks. Pain intensity, as well as pain-related disability, quality of life, and psychological status, were assessed. For the primary outcome, pain intensity was measured daily using a numerical rating scale as a pain diary. Thirty patients were randomly assigned to the active rTMS or sham-stimulation groups. In the primary outcome, the decrease (least square [LS] mean ± standard error) in the weekly average of a pain diary at week 9 compared to the baseline was 0.84 ± 0.31 in the active rTMS group and 0.58 ± 0.29 in the sham group (LS mean difference, 0.26; 95% confidence interval, - 0.60 to 1.13). There was no significant effect on the interaction between the treatment group and time point. Pain-related disability score improved, but other assessments showed no differences. No serious adverse events were observed. This study did not show significant pain relief; however, active rTMS tended to provide better results than sham. rTMS has the potential to improve pain-related disability in addition to pain relief.Clinical Trial Registration number: jRCTs052190110 (20/02/2020).
BibTeX
@inproceedings{mori2024repetitive,
  author = {Nobuhiko Mori and Koichi Hosomi and Asaya Nishi and Akimitsu Miyake and Tomomi Yamada and Akiyoshi Matsugi and Yasutomo Jono and Chanseok Lim and Hui Ming Khoo and Naoki Tani and Satoru Oshino and Youichi Saitoh and Haruhiko Kishima},
  title = {{Repetitive transcranial magnetic stimulation focusing on patients with neuropathic pain in the upper limb: a randomized sham-controlled parallel trial}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-62018-x},
}
Figure